p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M.
Hardwick NR, et al. Among authors: wilczynski s.
Clin Cancer Res. 2018 Mar 15;24(6):1315-1325. doi: 10.1158/1078-0432.CCR-17-2709. Epub 2018 Jan 4.
Clin Cancer Res. 2018.
PMID: 29301826
Free PMC article.
Clinical Trial.